المؤلفون: Wang, Yucai, albanyan, omar, Munoz, Javier, Rejeski, Kai, SESQUES, Pierre, IACOBONI, GLORIA, Barba, Pere

المساهمون: Institut Català de la Salut, Rejeski K Department of Medicine III – Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. Wang Y Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Albanyan O Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. Munoz J Division of Hematology and Oncology, Mayo Clinic, Phoenix, Arizona, USA. Sesques P Hospices Civils de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, Pierre-Bénite, France. Iacoboni G Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Medicine, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Limfomes - Tractament, Trastorns limfoproliferatius - Tractament, Cèl·lules T - Ús terapèutic - Efectes secundaris, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, Mantle-Cell, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Other subheadings::Other subheadings::Other subheadings::/adverse effects, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células del manto, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos

وصف الملف: application/pdf

العلاقة: American Journal of Hematology;98(11); https://doi.org/10.1002/ajh.27056Test; Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023 Nov;98(11):1699–710.; https://hdl.handle.net/11351/10464Test; 001051772500001

الإتاحة: https://doi.org/10.1002/ajh.27056Test
https://hdl.handle.net/11351/10464Test

المؤلفون: Perez, Ariel, Blumenberg , Viktoria, Bücklein, Veit, Völkl, Simon, Rejeski, Kai, IACOBONI, GLORIA, Barba, Pere

المساهمون: Institut Català de la Salut, Rejeski K, Blumenberg V, Bücklein VL Department of Medicine III – Hematology/Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich and Berlin sites, and German Cancer Research Center, Heidelberg, Germany. Bavarian Cancer Research Center (BZKF), partner sites, Munich and Erlangen, Germany. Perez A Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA. Blood and Marrow Transplant Program, Miami Cancer Institute, Miami, FL, USA. Iacoboni G, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Völkl S Bavarian Cancer Research Center (BZKF), partner sites, Munich and Erlangen, Germany. Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Càncer, Immunoteràpia, Cèl·lules T, Antígens CD, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, Other subheadings::Other subheadings::Other subheadings::/adverse effects, DISEASES::Neoplasms, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos, ENFERMEDADES::neoplasias

وصف الملف: application/pdf

العلاقة: Science Advances;9(38); https://doi.org/10.1126/sciadv.adg3919Test; Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, et al. Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion. Sci Adv. 2023 Sep 22;9(38):eadg3919.; https://hdl.handle.net/11351/10382Test

الإتاحة: https://doi.org/10.1126/sciadv.adg3919Test
https://hdl.handle.net/11351/10382Test

المؤلفون: Perez, Ariel, Jurinovic, Vindi, Holtick, Udo, Rejeski, Kai, IACOBONI, GLORIA, Bücklein, Veit

المساهمون: Institut Català de la Salut, Bücklein V Department of Medicine III, University Hospital, LMU Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Perez A Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA. Blood and Marrow Transplant Program, Miami Cancer Institute, Miami, FL, USA. Rejeski K Department of Medicine III, University Hospital, LMU Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center (DKFZ), Heidelberg, Germany. Iacoboni G Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Jurinovic V Institute for Medical Information Processing, Biometry, and Epidemiology, LMU Munich, Germany. Holtick U Department I of Internal Medicine, Medical Faculty and University Hospital, Cologne, University of Cologne, Germany, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cèl·lules B - Tumors - Immunoteràpia, Avaluació de resultats (Assistència sanitària), DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell, Other subheadings::Other subheadings::/therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B, Otros calificadores::Otros calificadores::/terapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento

وصف الملف: application/pdf

العلاقة: HemaSphere;7(8); https://doi.org/10.1097/HS9.0000000000000907Test; Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, et al. Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use. HemaSphere. 2023 Jul 11;7(8):e907.; https://hdl.handle.net/11351/10105Test; 001029914500001

الإتاحة: https://doi.org/10.1097/HS9.0000000000000907Test
https://hdl.handle.net/11351/10105Test

المؤلفون: Bosch-Schips, Jan, Serna, Angel, Abrisqueta, Pau, Nadeu, Ferran, IACOBONI, GLORIA, Cabirta, Alba, Bosch, Francesc

المساهمون: Institut Català de la Salut, Abrisqueta P, Iacoboni G, Serna A, Cabirta A, Bosch F Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Nadeu F Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Department of Pathology, Hospital Universitari de Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain. Bosch-Schips J Department of Pathology, Hospital Universitari de Bellvitge-Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Leucèmia limfocítica crònica - Complicacions, Trastorns limfoproliferatius - Tractament, DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Lymphoid::Leukemia, B-Cell::Leukemia, Lymphocytic, Chronic, B-Cell, Other subheadings::Other subheadings::Other subheadings::/complications, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::/therapy, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia de células B::leucemia linfocítica crónica de células B, Otros calificadores::Otros calificadores::Otros calificadores::/complicaciones, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::/terapia

وصف الملف: application/pdf

العلاقة: Cancer Treatment Reviews;120; https://doi.org/10.1016/j.ctrv.2023.102619Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01392; Abrisqueta P, Nadeu F, Bosch-Schips J, Iacoboni G, Serna A, Cabirta A, et al. From genetics to therapy: Unraveling the complexities of Richter transformation in chronic lymphocytic leukemia. Cancer Treat Rev. 2023 Nov;120:102619.; https://hdl.handle.net/11351/10286Test

الإتاحة: https://doi.org/10.1016/j.ctrv.2023.102619Test
https://hdl.handle.net/11351/10286Test

المؤلفون: Blumenberg, Viktoria, Iacoboni García-Calvo, Gloria, Kharboutli, Soraya, Hernani, Rafael, Barba Suñol, Pere, Lopez Corral, Lucia, Rejeski, Kai

المساهمون: Institut Català de la Salut, Rejeski K, Blumenberg V Department of Medicine III – Hematology/Oncology, University Hospital, LMU Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. Bavarian Cancer Research Center (BZKF), Partner Sites Munich and Erlangen, Germany. Iacoboni G, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament of Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. Lopez-Corral L Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain. Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain. Kharboutli S Bavarian Cancer Research Center (BZKF), Partner Sites Munich and Erlangen, Germany. Department of Internal Medicine 5, Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Germany. Hernani R Hematology Department, Hospital Clínico Universitario, INCLIVA Research Institute, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cèl·lules B - Tumors - Tractament, Cèl·lules T - Receptors, ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Artificial::Receptors, Chimeric Antigen, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::/therapy, ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores artificiales::receptores de antígenos quiméricos, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::/terapia

وصف الملف: application/pdf

العلاقة: HemaSphere;7(4); http://dx.doi.org/10.1097/HS9.0000000000000858Test; Rejeski K, Blumenberg V, Iacoboni G, Lopez-Corral L, Kharboutli S, Hernani R, et al. Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. HemaSphere. 2023 Apr;7(4):e858.; https://hdl.handle.net/11351/9433Test

الإتاحة: https://doi.org/10.1097/HS9.0000000000000858Test
https://hdl.handle.net/11351/9433Test

المؤلفون: Burchert, Andreas, SESQUES, Pierre, Fransecky, Lars, Rejeski, Kai, IACOBONI, GLORIA, Barba, Pere, Bücklein, Veit

المساهمون: Institut Català de la Salut, Rejeski K Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK), Munich Site, and German Cancer Research Center, Heidelberg, Germany. Burchert A Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany. Iacoboni G, Barba P Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. Sesques P Hospices Civils de Lyon, Universite Claude Bernard Lyon 1, INSERM 1052, Pierre-B enite, France. Fransecky L Medical Department II–Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany. Bücklein V Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cèl·lules mare, Estudis de viabilitat, Teràpia cel·lular, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Feasibility Studies, AND EQUIPMENT::Therapeutics::Salvage Therapy, ANATOMY::Cells::Stem Cells, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios de viabilidad, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::tratamiento de última línea, ANATOMÍA::células::células madre, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva

وصف الملف: application/pdf

العلاقة: Blood Advances;6(16); https://doi.org/10.1182/bloodadvances.2022007776Test; Rejeski K, Burchert A, Iacoboni G, Sesques P, Fransecky L, Bücklein V, et al. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy. Blood Adv. 2022 Aug 23;6(16):4719-25.; https://hdl.handle.net/11351/9612Test; 000863968700001

الإتاحة: https://doi.org/10.1182/bloodadvances.2022007776Test
https://hdl.handle.net/11351/9612Test

المؤلفون: Perez, Ariel, Iacoboni García-Calvo, Gloria, Penack, Olaf, Jentzsch, Liv, Carpio Segura, Cecilia Carmen, Barba Suñol, Pere, Rejeski, Kai, Bücklein, Veit

المساهمون: Institut Català de la Salut, Rejeski K Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. German Cancer Consortium (DKTK) Munich Site, and German Cancer Research Center, Heidelberg, Germany. Perez A Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, USA. Blood & Marrow Transplant Program, Miami Cancer Institute, Miami, Florida, USA. Iacoboni G, Carpio C, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma of Barcelona, Bellaterra, Spain. Penack O Department of Hematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. German Cancer Consortium (DKTK) Berlin Site, and German Cancer Research Center, Heidelberg, Germany. Bücklein V Department of Medicine III, Hematology and Oncology, University Hospital, LMU Munich, Munich, Germany. Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Jentzsch L Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cèl·lules B - Tumors - Tractament, Immunoteràpia, Antígens CD - Immunologia, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::/therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunization, Passive::Adoptive Transfer::Immunotherapy, Adoptive, CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Surface::Antigens, Differentiation::Antigens, CD::Antigens, CD19, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::/terapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunización pasiva::transferencia adoptiva::inmunoterapia adoptiva, COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos de superficie::antígenos de diferenciación::antígenos CD::antígenos CD19

وصف الملف: application/pdf

العلاقة: Journal for ImmunoTherapy of Cancer;10(5); http://dx.doi.org/10.1136/jitc-2021-004475Test; Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022 May;10(5):e004475.; https://hdl.handle.net/11351/8036Test; 000797594100008

الإتاحة: https://doi.org/10.1136/jitc-2021-004475Test
https://hdl.handle.net/11351/8036Test

المؤلفون: Ruiz-Rodriguez, Juan Carlos, Chiscano Camon, Luis, Ruiz Sanmartin, Adolfo, Palmada Ibars, Clara, Bajaña Mindiolaza, Ivan Rene, Bonilla Rojas, Camilo Andres, García Roche, Alejandra, Plata Menchaca, Erika Paola, Maldonado Toral, Carolina, Martínez Gallo, Mónica, Hernandez-Gonzalez, Manuel, Ferrer, Ricard, IACOBONI, GLORIA, Pérez Carrasco, Marcos, Franco-Jarava, Clara

المساهمون: Institut Català de la Salut, Ruiz-Rodríguez JC, Chiscano-Camón L, Ruiz-Sanmartin A, Plata-Menchaca E, Pérez-Carrasco M, Ferrer R Servei de Medicina Intensiva, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Shock, Disfunció Orgànica i Ressuscitació, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Palmada C, Bajaña I, Bonilla C, García-Roche A, Maldonado C Servei de Medicina Intensiva, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca de Shock, Disfunció Orgànica i Ressuscitació, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d'Hebron Hospital Universitari, Barcelona, Spain. Iacoboni G Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Hematologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Martinez-Gallo M Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei d’Immunologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca d’Immunologia Translacional, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain. Franco-Jarava C Servei d’Immunologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca d’Immunologia Translacional, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Hernández-González M Servei d’Immunologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca d’Immunologia Translacional, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Biologia Cel·lular, Fisiologia i Immunologia, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Citocines, Macròfags, Cèl·lules - Proliferació, DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Histiocytosis::Histiocytosis, Non-Langerhans-Cell::Lymphohistiocytosis, Hemophagocytic, Other subheadings::Other subheadings::/therapy, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Sorption Detoxification::Hemoperfusion, ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::hisitiocitosis::histiocitosis de células no Langerhans::linfohistiocitosis hemofagocítica, Otros calificadores::Otros calificadores::/terapia, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::desintoxicación por adsorción::hemoperfusión

وصف الملف: application/pdf

العلاقة: Frontiers in Medicine;9; https://doi.org/10.3389/fmed.2022.925751Test; Ruiz-Rodríguez JC, Chiscano-Camón L, Ruiz-Sanmartin A, Palmada C, Bajaña I, Iacoboni G, et al. Case report: Cytokine hemoadsorption in a case of hemophagocytic lymphohistiocytosis secondary to extranodal NK/T-cell lymphoma. Front Med. 2022 Aug 15;9:925751.; https://hdl.handle.net/11351/9699Test; 000848072000001

الإتاحة: https://doi.org/10.3389/fmed.2022.925751Test
https://hdl.handle.net/11351/9699Test

المؤلفون: BASTOS, MARIANA, GUTIERREZ, ANTONIO, Reguera, Juan Luís, Iacoboni García-Calvo, Gloria, Lopez Corral, Lucia, Terol, M. Jose, Abrisqueta, Pau, Barba Suñol, Pere

المساهمون: Institut Català de la Salut, Bastos-Oreiro M Hospita Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. Gutierrez A Hospital Universitario Son Espases, Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Palma de Mallorca, Spain. Reguera JL Hematology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. Iacoboni G, Abrisqueta P, Barba P Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. López-Corral L Hospital Universitario de Salamanca, Instituto de investigación biomédica de Salamanca (IDBAL), CIBERONC, Salamanca, Spain. Terol MJ Hematology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Cèl·lules T, Cèl·lules B - Tumors - Tractament, Teràpia cel·lular, ANATOMY::Cells::Blood Cells::Leukocytes::Leukocytes, Mononuclear::Lymphocytes::T-Lymphocytes, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse, Other subheadings::Other subheadings::/therapy, ANATOMÍA::células::células sanguíneas::leucocitos::leucocitos mononucleares::linfocitos::linfocitos T, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::tratamientos basados en células y tejidos, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso, Otros calificadores::Otros calificadores::/terapia

وصف الملف: application/pdf

العلاقة: Frontiers in Immunology;13; https://doi.org/10.3389/fimmu.2022.855730Test; Bastos-Oreiro M, Gutierrez A, Reguera JL, Iacoboni G, López-Corral L, Terol MJ, et al. Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups. Front Immunol. 2022 Jul 12;13:3148.; https://hdl.handle.net/11351/9555Test; 000834262500001

الإتاحة: https://doi.org/10.3389/fimmu.2022.855730Test
https://hdl.handle.net/11351/9555Test

المؤلفون: Abrisqueta, Pau, Medina Gil, Daniel, Lu, Junyan, Alcoceba, Miguel, Carabia Juberó, Júlia, Boix, Joan, Tazón Vega, Bárbara, Iacoboni García-Calvo, Gloria, Bobillo Varela, Sabela, González, Marcos, Zenz, Thorsten, Crespo Maull, Marta, Bosch Albareda, Francesc, Villacampa Javierre, Guillermo, Marin Niebla, Ana

المساهمون: Institut Català de la Salut, Abrisqueta P, Tazón-Vega B, Iacoboni G, Bobillo S, Marín-Niebla A, Bosch F Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Medina D, Carabia J, Boix J, Crespo M Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Villacampa G Oncology Data Science (OdysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Lu J European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. Alcoceba M, González M Department of Hematology, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Center for Cancer Research-IBMCC (USAL-CSIC), Salamanca, Spain. Zenz T Department of Medical Oncology and Hematology, University Hospital and University of Zurich, Zurich, Switzerland, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Marcadors tumorals, Expressió gènica, Leucèmia limfocítica crònica, DISEASES::Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Lymphoid::Leukemia, B-Cell::Leukemia, Lymphocytic, Chronic, B-Cell, Other subheadings::Other subheadings::Other subheadings::/genetics, PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Microenvironment::Tumor Microenvironment, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis, PHENOMENA AND PROCESSES::Genetic Phenomena::Gene Expression, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::leucemia::leucemia linfoide::leucemia de células B::leucemia linfocítica crónica de células B, Otros calificadores::Otros calificadores::Otros calificadores::/genética, FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::microambiente celular::microambiente tumoral, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico, FENÓMENOS Y PROCESOS::fenómenos genéticos::expresión génica

وصف الملف: application/pdf

العلاقة: Blood Advances;6(21); https://doi.org/10.1182/bloodadvances.2022007508Test; info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00950; info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F00943; info:eu-repo/grantAgreement/ES/PE2013-2016/PI18%2F01392; Abrisqueta P, Medina D, Villacampa G, Lu J, Alcoceba M, Carabia J, et al. A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression. Blood Adv. 2022 Nov 8;6(21):5763–73.; https://hdl.handle.net/11351/8701Test

الإتاحة: https://doi.org/10.1182/bloodadvances.2022007508Test
https://hdl.handle.net/11351/8701Test